Galen was founded in Craigavon, Northern Ireland in 1968 by the late Sir Allen McClay (d. 2010), the revered philanthropist and entrepreneur.

Sir Allen invested in research and innovation, to ensure the latest advances in healthcare would be available to all, and to foster employment opportunities locally. In 1997, Galen became Northern Ireland’s first £1 billion company and in 2002, Sir Allen formed what is now known as the Almac Group.

Galen is proud member of the Almac Group of world-class companies in the pharmaceutical and biotech sectors. The Group is wholly owned by the McClay Foundation, whose overarching aim is to make a meaningful improvement and advancement in human health.

We champion the values upon which Galen was built and remain passionate about Sir Allen’s mission to improve and optimise human health, and to achieve a meaningful impact on patients' lives.

At Galen, we have purpose and passion in everything we do and encourage our people to dare to be extraordinary so we can benefit the health of all generations.

We are privately owned pharmaceutical company established in 1968, with global headquarters in Craigavon, Northern Ireland, and commercial operations based in the UK, Ireland, the Nordics, Europe, and the USA.

Galen’s focus is selling medicines worldwide in the areas of pain management, dermatology, and gastroenterology. We are committed to customer care and partner with like-minded companies to accomplish this.

Through organic growth and acquisitions, we have established product sales in 25 locations. We continue to actively seek new markets and new opportunities, expanding to offer a global reach from our base in Northern Ireland.

As a proud member of the Almac Group of world-class companies in the pharmaceutical and biotech sectors, we have access to a wide variety of services and expertise, from drug discovery to commercial-scale manufacture.

By combining innovation in product development with competitive pricing, we work together, in partnership with healthcare professionals and patients to create real, long-term value, a major factor in our success to date.

Our expertise lies in:

• sales, marketing and launch excellence
• market access
• regulatory affairs, pharmacovigilance and medical affairs
• supply chain and logistics.